N/A N=36 Treatment for Nicotine Addiction in Women
Nicotine Dependence
Primary: Withdrawal Symptoms (MNWS Score) — 13.33; 9.40; 11.95; 13.29 score on a scale — p=0.18
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
Phase 2 N=67 Translational Neuropsychopharmacology Research of Nicotine Addiction
Nicotine Dependence, Cigarettes
Primary: Percent Change in Blood Oxygen Level Dependent (BOLD) Signal Response — -0.09; 1.07; 0.08; 1.19 Percentage change
N/A N=78 Nicotine and Behavior in Adult ADHD
ADHD
Primary: ADHD Symptoms — 71.2; 78.4; 47.4; 55.5 Percent of item endorsement — p=<0.025
N/A N=25 Nicotine Receptor Levels and Smoking Cessation
Smoking Cessation · Nicotine Addiction
Primary: Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging. — 17.5; 26.8 Distribution Volume Ratio (Vt/fp) — p=0.037
Early Phase 1 N=34 Nicotine Reinforcement and Aversion in Young Adult Light Smokers
Nicotine Addiction
Primary: DEQ - Pleasurable — 2.14; 2.05; 1.98; 2.37 score on a scale
N/A N=112 Nicotine Withdrawal Symptoms and Smoking Relapse
Nicotine Dependence
Primary: BOLD Activation in Right ACC During Parametric Flanker Task tDCS Stimulation — 1.051567464; 0.867749333; 0.8973946; 1.143702607 Percent BOLD change
N/A N=56 Medicinal Nicotine for Preventing Cue Induced Craving
Tobacco Use Disorder
Primary: Craving Symptom Severity Score Assessed Via Questionnaire — 0.52; 0.57; 0.31 units on a scale — p=0.25
N/A N=42 Repetitive Transcranial Magnetic Stimulation (rTMS) for Nicotine Addiction
Nicotine Dependence
Primary: Nicotine Consumption: Number of Cigarettes Per Day — 11.60; 13.73 the number of cigarette — p=0.05
Phase 4 N=47 Nicotine Replacement Therapy in the Intensive Care Unit
Delirium · Psychomotor Agitation · Substance Withdrawal Syndrome
Primary: 30-day Mortality — 9.5; 7.7 percentage of patients
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Early Phase 1 N=16 Nicotine's Potential Abuse With Menthol
Nicotine Dependence
Primary: Drug Effect Questionnaire - Stimulatory Effects — 39.37; 33.48; 32.35; 33.23 units on a scale — p=0.93
N/A N=12 Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
Tobacco Use Disorder
Primary: Cigarette Choice After 3 Day Abstinence — 2.50; 3.67 number of cigarette choices (0-6)
Phase 3 N=1,246 Pharmacogenetics of Nicotine Addiction Treatment
Nicotine Addiction
Primary: 7-day Point Prevalence Quit Rate at End-of-Treatment (EOT) — 17.2; 18.6; 27.7; 22.5 percentage of ITT subjects
N/A N=54 Acute and Chronic Nicotine Modulation of Reinforcement Learning
Nicotine Addiction
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signal in Dorsomedial Prefrontal Cortex — 7.3; 6.3; 6.2; .02 percentage of BOLD signal
Phase 2 N=24 Effects of Semaglutide on Nicotine Intake
Tobacco Use Disorder · Nicotine Addiction
Primary: Change in Nicotine Self-Administration — -0.8; -0.5 Number of cigarettes
Phase 3 N=74 Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence
Smoking Cessation
Primary: Change in the Skin Conductance Level, Caused by Smoking Cues, Measured Using Script Driven Imagery — 0.107; -0.040 µS — p=0.05
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
N/A N=38 Clinical Pharmacology of Electronic Cigarettes
Nicotine Dependence
Primary: Standardized Session: Mean CMax — 6.1; 20.2 ng/mL
Phase 4 N=127 Nicotine Patch for Marijuana Withdrawal
Marijuana Dependence
Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=15 Nicotine Related Brain Activity: The Influence of Smoking History and Blood Nicotine Levels
Nicotine Dependence
Primary: Peak Nicotine Levels — 16.1; 0 ng/ml
N/A N=17 Varenicline and Nicotine Interactions in Humans (VA)
Smoking Cessation
Primary: Subjective Responses to Intravenous Nicotine — 23; 38; 51; 14 millimeters — p=<0.05
Phase 4 N=25 Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging
Nicotine Dependence
Primary: Change in Mu-opioid Receptor Binding Potential (BP) Between Baseline and Post-patch Scans — -2.47; -5.94; 5.60; -1.24 ratio
Phase 4 N=126 Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers
Nicotine Dependence
Primary: Changes in Log Brain-wave (EEG) Activity (Power [Microvolts Squared]) From Pre-quit Baseline to 66 Days Post-quit, Assessed at 3, 24, 45, and 66 Days Post-quit. — .055…
N/A N=163 Behavioral Memory Modulation in Nicotine Addiction
Nicotine Use Disorder
Primary: Mean Craving Questionnaire Score, Response to the Novel Cue — 3.43; 3.73; 2.55; 2.88 score on a scale, average of 4 responses
Phase 3 N=58 Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence
Tobacco Dependence · Nicotine Dependence
Primary: Fageström Test for Nicotine Dependence Score at Baseline and After 90 Days of the Treatment — 6.53; 6.56; 5.96; 5.22 units on a scale
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05